Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PB101 in EGFR-mutated advanced NSCLC
NCT07271446Phase 1Completed
- Sponsor
- Precision BioSciences, Inc.
- Start
- Sep 2018
- Primary completion
- Aug 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PB101 in non-small cell lung cancer (NSCLC), sponsored by Precision BioSciences, Inc. Primary endpoints: Adverse events at 1 year and Severe Adverse events at 1 year. Started Sep 2018; status: completed.
02
Drugs
PB101
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07271446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07271446.